BUSINESS
In a battle over a Rs 250-cr product, Novartis is unwilling to yield an inch
Novartis' Diclofenac injection 75 mg/1 ml was recently banned at the behest of Indian drug regulator after complaints by a little known Ahmedabad-based company, which had a competing product
BUSINESS
The curious case of Oxytocin retail ban by government
The government said the curbs on oxytocin is to restrict the abuse of the hormonal drug by dairy industry on animals.
BUSINESS
Torrent Pharma Q1 profit drops 13% to Rs 162 cr on higher amortisation, finance costs
Torrent Pharma bought domestic formulation business of Unichem Laboratories Rs 3600 crore in December 2017.
BUSINESS
Healthtech disruption: An AI a day helps the doctor a long way
One area that’s ripe for disruption is diagnostics – as successful diagnosis depends on recognition of patterns, mostly visual. That is where AI has an edge compared to humans.
BUSINESS
Delhi HC asks Singh brothers to personally appear for proceedings in Daiichi case
The summons were issued as the court wasn't satisfied with the information provided by Singh brothers on the status of their assets under possession.
BUSINESS
Ayushman Bharat: Insurance companies left in lurch as states opt for trust-based models
In a trust-based model, each state will form its own trust to manage the scheme and claims will be paid from a corpus created from central and state government contributions
BUSINESS
Piramal Enterprises may consider sale of analytics unit if growth doesn't pick up
Will unlock value if topline and profitability of Decision Resources Group (DRG) doesn't go up significantly, says Ajay Piramal
BUSINESS
Piramal Enterprises June quarter loss at Rs 70 crore, hit by one-time charge on imaging biz sale
Excluding the exceptional item - the June quarter net profit grew 27 percent to Rs. 382 crore, on back of strong growth in its financial services and pharmaceutical businesses.
BUSINESS
Dr Reddy's gets expedited hearing of injunction against its launch of gSuboxone in US
Under the expedited schedule ordered by the US Court of Appeals for the Federal Circuit, arguments will be held during the first week of October
BUSINESS
Pharma this week: No relief! Expert panel recommends continuation of govt ban on 343 FDCs
The panel also pointed out that many of these FDCs were formulated without due diligence and the dosing mismatches could result in toxicity that may adversely impact vital organs like liver
BUSINESS
Biocon Q1 net profit jumps 47% to Rs 120 crore, beats analyst estimates
Total revenue for the quarter under review grew 21 percent to Rs 1,192 crore in the April-June period.
BUSINESS
Dr Reddy's profit grows eight-fold on higher sales in India, US & emerging markets
Revenue during the quarter grew 12 percent to Rs 3,721 crore compared to Rs 3,316 crore in the same quarter last year.
BUSINESS
SRL looks to inject new lease of life into biz, rolls out wellness-themed marketing plan
SRL which contributes about one-fifth of Fortis revenues of Rs 4537 crore in FY18, has been struggling to grow its margins and revenues faced with competition and pricing pressure.
BUSINESS
EXCLUSIVE | Govt commissions study on package rates under Modicare, open to revise rates
Niti Aayog and ICMR are tasked to do undertake a detailed study that aims to examine the cost of each procedure and arrive at a suitable package rate.
BUSINESS
Pharma weekly wrap: Daiichi seeks stay on Fortis-IHH deal, Q1 results
The shareholders of Fortis are scheduled to meet at an extraordinary general meeting in Delhi on August 13 to approve IHH’s offer.
BUSINESS
Exclusive | West Bengal to join Modicare, sign MoU with Centre soon
Unlike most other states who are following a trust based model wherein claims are settled from a corpus created from contributions from central and state governments, West Bengal will run the scheme through insurance model which means the state will buy cover from the insurance company that quotes the lowest premium.
BUSINESS
IHH wins Fortis bid — Meet CEO Tan See Leng, a bus timekeeper's son key to Malaysian co's rise to the top
"I think one of the key things about such a great, deep, and long learning curve is that during the process of learning what to do, I think we have also learned the more important lesson of what not to do," Tan said in call to analysts referring to Company's India business.
BUSINESS
Portea to turn profitable in next 18 months, looks at acquisitions in multiple segments
The company's founder said that the company is sufficiently funded, and is constantly looking at segments like nutrition, mental health and tele-medicine for acquisitions
BUSINESS
Daiichi seeks stay on Fortis-IHH deal, cites Rs 3,500-cr arbitration case against Singh bros
The court has asked Fortis and the Singh brothers, Malvinder and Shivinder, to respond to Daiichi's application by the next hearing scheduled on August 1.
BUSINESS
Pharma weekly wrap: IHH may get its offer approved, but getting Fortis back on track remains a challenge
To consummate the deal, the IHH offer will now need the approval of Fortis' shareholders and the Competition Commission of India (CCI). According to the Fortis board, all this should not take more than 75 days
BUSINESS
Aurobindo to acquire Apotex ops in 5 European nations for 74 million euros
The Hyderabad-based drug firm has inked definitive agreement to acquire commercial operations and certain supporting infrastructure from Apotex International Inc.
BUSINESS
IHH CEO says top priority is to stablise and secure Fortis Healthcare
Tan said IHH has developed a 100-day turnaround plan to improve the operating margins by around 500-600 basis points.
BUSINESS
Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz
"For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities
BUSINESS
As Modicare deadline nears, govt struggles to get private hospitals on board
On an average, the rates proposed under the scheme are almost 30-45 percent lower than what a hospital would normally charge
